title: An unusual case of refractory Campylobacter jejuni infection in a patient with X-linked agammaglobulinemia: successful combined therapy with maternal plasma and ciprofloxacin.
abstract: An unusual hippurate-negative strain of Campylobacter jejuni caused a chronic refractory infection in a patient with X-linked agammaglobulinemia; this infection persisted for > 2 years despite therapy with various antibiotics and immunoglobulins (Igs). To characterize the defense status of this patient, several in vitro studies, including those with T cells and polymorphonuclear leukocytes (PMNLs), were performed. T cell responses specific for C. jejuni were only weak in this patient. Chemiluminescence and bacterial killing studies with PMNLs revealed that the bactericidal activity of PMNLs against Campylobacter was enhanced more vigorously by maternal serum than by commercial Ig preparations. On the basis of these results, combined treatment with ciprofloxacin and maternal plasma was initiated, and the C. jejuni infection was rapidly cured. This case report shows that in vitro immunologic assays may be useful for characterizing immune functions of patients with chronic or refractory C. jejuni infections, thus leading to individual treatment strategies.
authors.affiliation: Institut für Hygiene und Mikrobiologie, Universität Würzburg, Germany.
authors.forename: I B
authors.initials: IB
authors.lastname: Autenrieth
authors.forename: V
authors.initials: V
authors.lastname: Schuster
authors.forename: J
authors.initials: J
authors.lastname: Ewald
authors.forename: D
authors.initials: D
authors.lastname: Harmsen
authors.forename: H W
authors.initials: HW
authors.lastname: Kreth
mesh_terms: D019264:Adoptive Transfer; D000361:Agammaglobulinemia / Q000150:complications* / Q000276:immunology; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002169:Campylobacter Infections / Q000150:complications* / Q000276:immunology / Q000628:therapy; D016123:Campylobacter jejuni / Q000302:isolation & purification; D002648:Child; D002939:Ciprofloxacin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004269:DNA, Bacterial / Q000032:analysis; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008163:Luminescent Measurements; D008297:Male; D017192:Skin Diseases, Bacterial / Q000150:complications* / Q000276:immunology / Q000628:therapy
chemical_list: D000890:Anti-Infective Agents; D004269:DNA, Bacterial; D002939:Ciprofloxacin